Elevance Health Inc
ELV
New York Stock Exchange. Currency in USD
502.89 +0.84 ( +0.17% )
Market Cap.
120.10B
Beta (5Y monthly)
0.90
Price/Earnings
17.93
EPS (TTM)
28.96
Forward Dividend
5.12 (0.98%)
Ex-Dividend Date
Dec 05, 2022
Volume
745,749
1y Target Est.
568.43
Day's Range
52 Week's Range
Historical Summary
Performance
1 Month
1.53%
YTD
692.39%
1Y
692.39%
2Y
692.39%
181.69% ann.
3Y
692.39%
99.33% ann.
5Y
692.39%
51.29% ann.
10Y
692.39%
23.00% ann.
EPS growth
1Y
23.92%
2Y
21.89%
10.41% ann.
3Y
61.07%
17.22% ann.
5Y
132.42%
18.38% ann.
10Y
288.20%
14.53% ann.
20Y
1,377.55%
14.41% ann.
Share Buybacks
3 Months
-0.00%
6 Months
0.41%
1Y
1.06%
2Y
4.25%
3Y
6.38%
5Y
8.84%
10Y
24.39%
20Y
8.30%
About Elevance Health Inc
Sector
Healthcare
Industry
Healthcare Plans
Website
https://www.elevancehealth.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
241.08M
Employees
98200
Address
220 Virginia Avenue, Indianapolis, IN, United States, 46204
Latest news

ELV vs. PGNY: Which Stock Is the Better Value Option?
ELV vs. PGNY: Which Stock Is the Better Value Option?
By Zacks Investment Research - 6 weeks ago

Cigna (CI) Hits 52-Week High: What's Driving the Stock?
Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth...
By Zacks Investment Research - 6 weeks ago

Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared...
By Zacks Investment Research - 7 weeks ago

Humana (HUM) Rises 23% in Past 6 Months: More Room to Run?
Humana (HUM) is well-poised for growth on improving revenues, numerous contract wins and adequate cash-generating...
By Zacks Investment Research - 7 weeks ago

Acadia (ACHC) Reveals its Long-Term Goals: What You Should Know
From 2022 to 2028, Acadia Healthcare (ACHC) expects to see a 9-11% CAGR in revenues.
By Zacks Investment Research - 7 weeks ago

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics
The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing...
By Zacks Investment Research - 7 weeks ago

Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023
Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in...
By Zacks Investment Research - 7 weeks ago

Centene (CNC) Concludes Magellan Rx Divestment to Prime
Centene (CNC) completes Magellan Rx divestment within the scheduled time.
By Zacks Investment Research - 7 weeks ago